Mark Brandt

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Farhad Ravandi1
Mark Routbort1
Elias Jabbour1
Hagop Kantarjian1
1Farhad Ravandi
1Mark Routbort
1Elias Jabbour
1Hagop Kantarjian
Learn More
Letter to Editor Recurrent pathogenic mutations in IDH1 and IDH2 at the conserved amino acid sites IDH1-R132, IDH2-R140 and IDH2-R172 occur in approximately 20% of patients with acute myeloid leukemia (AML).(1) A recent analysis of AML patients at our institution identified IDH1/2 mutations in 20% (n=167) of 826 AML patients, with IDH1/2 mutations occurring(More)
  • 1